Neoplasms

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 5, 2025 /PRNewswire/ --The integration of artificial intelligence (AI) into healthcare is here to stay, and adoption is accelerating. According to research from PYMNTS Intelligence which polled C-suite executives at healthcare companies generating at least $1 billion in annual revenue, 90% already see positive ROI from investments in generative AI (GenAI). Analysts are projecting that by 2035 the gross value added by AI to the healthcare industry will be $461 billion on top of a baseline $2.26 trillion. Behind the scenes, several new AI healthcare tech developments are taking place, with updates recently coming from Avant Technologies, Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM), Tevogen Bio Holdings Inc. (NASDAQ: TVGN), GE HealthCare Technologies Inc. (NASDAQ: GEHC), and Schrödinger, Inc. (NASDAQ: SDGR). At the regulatory level, the World Health Organization (WHO) recently announced a major global initiative to set unified standards for AI in healthcare, the US Food and Drug Administration (FDA) is working to catch up on approving new AI tech in the sector, with the latest being a cardioverter defibrillator. Avant Technologies, Inc. (OTCQB: AVAI), an emerging leader in AI-driven healthcare innovation, continues to accelerate its push into AI-powered healthcare diagnostics through its joint venture with Ainnova Tech, operating through Ai-nova Acquisition Corp. (AAC), a jointly controlled entity that holds global licensing rights to VisionAI and its supporting hardware. The two companies recently announced that the FDA has officially received their request for a pre-submission meeting for VisionAI, the joint venture's flagship screening platform. This marked a pivotal moment in Avant's trajectory. VisionAI uses a combination of retinal imaging, patient vitals, and advanced algorithms to identify early warning signs of diabetic retinopathy, cardiovascular disease, liver fibrosis, kidney disease, and type 2 diabetes—often before symptoms are visible. Studies show that AI tools can detect diabetic retinopathy and other chronic conditions with sensitivities exceeding 90%, often identifying issues before symptoms appear—according to NIH. "This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where VisionAI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vinicio Vargas, CEO at Ainnova and a member of AAC's Board of Directors. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product." The upcoming FDA meeting will help finalize the clinical trial design and confirm the regulatory pathway for a 510(k) submission in the U.S., setting the stage for broader deployment. What sets AVAI apart from many AI-in-healthcare names is that its technology is already in the field. VisionAI has been rolled out through commercial pilot programs across Latin America, including Chile, the Dominican Republic, Mexico, and Brazil. These early deployments are generating real-world data while demonstrating how early diagnostics can reduce system-wide costs and improve outcomes in primary care environments. In recent months, AAC expanded its portfolio with four newly licensed diagnostic algorithms from one of Asia's largest healthcare networks, validated on more than 2.3 million clinical cases. These models are now integrated into VisionAI to enhance its detection capabilities across multiple chronic disease categories. On the clinical development front, Avant's partner Ainnova has brought on global contract research organization Fortrea to help guide its FDA strategy. With both emerging-market traction and U.S. regulatory progress advancing in parallel, the company appears to be executing on a dual-pronged strategy: building early market access where regulatory barriers are lower, while preparing for the commercial scale and reimbursement potential of the U.S. healthcare system. For investors tracking small-cap companies operating at the intersection of AI, diagnostics, and chronic disease management, Avant Technologies may be worth a closer look. As the FDA process moves forward and pilot programs scale, AVAI sits in a rare position—commercially active, globally licensed, and now formally in dialogue with U.S. regulators. Tempus AI, Inc. (NASDAQ: TEM) recently expanded its support for phase I clinical trials by launching the TIME Precision Network, a group of investigators across over 40 research centers focused on rapid activation and enrollment. "The integration of phase I clinical trial sites adds a critical capability to the TIME Network,"said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "We are now able to activate and efficiently execute these early studies that are fundamental to drug development and such a valuable offering to patients. The reality is that these studies require specific and coordinated infrastructure to be successful, and I am proud that Tempus can now work with these sites and our life science partners to enroll patients into these cutting-edge clinical trials." Recent examples include first-patient-in enrollments within weeks at multiple cancer centers, showcasing the network's efficiency in matching patients to studies. By integrating community oncology sites and streamlining site activation, Tempus is lowering access barriers to early-stage trials across underserved regions. Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is advancing its AI-driven precision medicine capabilities through a new partnership with Databricks, focused on accelerating the development of its PredicTcell platform. The collaboration will enhance Tevogen's ability to model immunologically active peptide complexes and predict T cell receptor (TCR) engagement. This builds on the company's ExacTcell™ platform and complements other strategic alliances under the Tevogen.AI umbrella, including support from Microsoft Research. Together, these efforts aim to integrate clinical immunology with cutting-edge AI to fast-track the discovery and development of next-generation T cell therapies. GE HealthCare Technologies Inc. (NASDAQ: GEHC) is deepening its commitment to AI-driven oncology solutions with the launch of MR Contour DL, a new FDA-cleared model for organ segmentation in radiation therapy planning. "We're committed to advancing MR imaging capabilities in radiation therapy to deliver more accurate and precise care," said Kelly Londy, President and CEO, MR, GE HealthCare. "The anticipated addition of Spectronic's software offering to our portfolio would support our vision for an MR-based radiation oncology workflow and would help enable high-precision treatment planning for radiotherapy patients across the globe." The company also announced its intent to integrate Spectronic Medical's MRI Planner software to support MR-only workflows across global radiotherapy centers. These tools are being folded into the expanded Intelligent Radiation Therapy (iRT) solution, which now supports third-party AI applications and accelerates the treatment timeline. By combining MR imaging, automation, and deep learning, GE HealthCare aims to raise the precision and accessibility of radiotherapy worldwide. Schrödinger, Inc. (NASDAQ: SDGR) recently presented new preclinical data at AACR 2025 on two targeted cancer therapies developed using its proprietary computational platform. Among the findings, a machine learning model predicted synergistic drug combinations for its Wee1 inhibitor SGR-3515, enhancing its potential use across multiple tumor types. "The preclinical data for SGR-3515 and SGR-4174 further demonstrate that molecules discovered and developed by Schrödinger have favorably differentiated molecular profiles compared to existing development-stage molecules," said Karen Akinsanya, Ph.D, President of R&D therapeutics at Schrödinger. "The preclinical profiles of these development candidates reinforce the power of our computationally-driven approach to designing molecules that meet challenging target product profiles and have the potential for meaningful benefit to patients." The company's AI-driven discovery approach continues to yield differentiated molecules with promising therapeutic profiles. As AI continues to evolve from concept to clinical application, these companies are quietly shaping the future of medicine at the infrastructure level. With regulatory momentum building and real-world deployments expanding, investors may want to pay attention as this shift begins to accelerate. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Logo: SOURCE Equity Insider WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SAN DIEGO, CA, USA I May 05, 2025 I Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the initiation of Phase 1b expansion studies in the ongoing ENGAGER-PSMA-01 trial. ENGAGER-PSMA-01 is a first-in-human, open-label, multicenter Phase 1 clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of JANX007 administered as monotherapy or in combination in adult patients with advanced metastatic castration-resistant prostate cancer (mCRPC). In December 2024, Janux reported positive interim clinical data from the Phase 1a dose escalation portion of the trial in 16 mCRPC patients with a median of four prior lines of therapy. At that time, the median radiographic progression-free survival (rPFS) reported was 7.4 months for all 16 patients.* As of April 21, 2025, updated results** have been achieved in the same 16 patients supporting the initiation of the Phase 1b expansion studies: *8/16 patients were noted as in-progress in the December 2024 reported results. **rPFS results based upon Kaplan-Meier estimate. In addition, Janux has selected a CRS-mitigation strategy to support the initiation of the Phase 1b expansion studies that is designed to maintain the CRS profile reported in December. The first Phase 1b expansion study will enroll taxane-naïve mCRPC patients and is designed to generate additional safety and efficacy data in this first and second line (1L/2L) patient population. This study will assess JANX007 monotherapy at two dose regimens (0.3/2/6mg and 0.3/2/9mg) with dosing administered once weekly or once every two weeks in mCRPC patients who have progressed on or after novel hormonal therapy (NHT). “Initiation of the taxane-naïve study marks an important step as we begin to evaluate JANX007 in earlier-line mCRPC patient populations,” said Zachariah McIver, D.O., Ph.D., Chief Medical Officer of Janux. “While therapeutic options for mCRPC have expanded, there remains a significant need for novel, non-chemotherapeutic approaches.” Janux plans to initiate three additional Phase 1b expansion studies, evaluating: “Improved efficacy and durability of responses has been observed by other prostate cancer drugs and TCEs when moving into earlier lines of therapy. There are also indications that safety with TCEs improve in earlier lines of therapy where disease burden is lower. We believe that these observations, coupled with the data seen in our Phase 1a dose escalation in later line patients, strongly support our decision to develop JANX007 in earlier lines of therapy,” said David Campbell, Ph.D., President and CEO of Janux. Additional data from JANX007 and JANX008 will be presented at future Janux events in the second half of 2025. Separately, Janux will host an R&D Day in mid-2025 highlighting product candidates identified from its preclinical pipeline to move into clinical trials. Janux’s TRACTr and TRACIr Pipeline Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline. About Janux Therapeutics Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn. SOURCE: Janux Therapeutics

This historic acquisition reduces barriers that prevent people from taking control of their lifelong health. Full Body MRI scan now takes just 22 minutes instead of 60 minutes, costs $499 instead of over $1,500 NEW YORK, May 5, 2025 /PRNewswire/ -- Function Health has acquired Ezra and is launching a Full Body MRI with an FDA-cleared AI that cuts scan time from 60 minutes to 22 minutes, and $1500 to $499. This dramatic reduction in both time and cost makes annual scanning possible, creating a more comprehensive 360-degree view inside your body. By combining Function's extensive lab testing foundation with Ezra's FDA-cleared AI-powered imaging, they've integrated these two approaches into one seamless platform designed to keep you healthy for life. Function and Ezra together represent the exact data needed to create the new standard of care. By merging Function's extensive lab testing with Ezra's imaging, they're creating a dataset that will allow AI to become truly predictive—potentially identifying health issues before they occur. "I wish I could see millions of patients," says Mark Hyman, MD, co-founder and Chief Medical Officer of Function Health. "This is the most powerful approach I've seen in my entire career—and for the first time, it can truly scale to millions. It's the new standard of care—if you're reading this: get your labs, get your scan, every year. It could save and radically improve your life." The new 22-minute Full Body MRI is designed to help detect cancer early—often prior to any symptoms. Beyond cancer, the scan can also reveal hidden issues you otherwise might not know about, like silent strokes that could lead to cognitive decline and developing aneurysms before they rupture. Additional scans now being offered by Function look for spinal issues affecting mobility, early-stage fatty liver disease, and body composition details more precise than what DEXA scans provide. "Adding imaging was part of our vision from day one," says Jonathan Swerdlin, co-founder and CEO of Function Health. "Our brilliant team first focused on making comprehensive lab testing affordable and widely available. Now with Ezra becoming a part of Function, we complete the picture. It's time everyone owns their health, every year. This is the best use of AI—applying it directly to human life." Before AI, annual full body scans were simply not possible at scale. The prohibitive cost and lengthy scan times meant they could only be done as one-off procedures for a select few. AI has fundamentally changed this equation. For half the scan time and a third of the price, scanning every year is now practical and affordable. "A single health snapshot is like one frame from a movie—you miss the story," says Dan Sodickson, MD, PhD, Chief Scientific Advisor of Ezra. "Finally, reducing the cost and scan time of full body MRI unlocks the ability to capture an annual imaging baseline. This longitudinal dataset reveals subtle changes over time that catch immediate issues and can predict disease before symptoms even appear. This fundamentally transforms medicine." By making advanced MRI technology more affordable and accessible, Function is establishing a new standard of health. The integration creates a more complete view of individuals' health, combining detailed lab testing with advanced medical imaging in a single, cohesive platform, at an affordable price. "I started Ezra with a clear mission: to detect cancer early for everyone in the world," says Emi Gal, founder of Ezra. "This mission is deeply personal for me—if my mother had detected cancer early, she would still be alive today. Over the past six years my team and I have helped countless people find cancer, many of whom are now cancer free. We are now scaling this to millions together with Function." Scans are now immediately available for every Function member at nearly 100 locations across the US, with plans to expand to over 1,000 locations in the coming months. Function's lab testing platform is already available at all 2,200 Quest Diagnostics locations nationwide. AI is revolutionizing healthcare beyond language models. Ezra's FDA-cleared AI technology cuts scan time from 60 minutes to 22 minutes, while Function's nationwide platform makes these scans accessible to members across the country. This transforms yesterday's luxury into today's essential—Full Body MRI scans at $499 instead of $1,500. For more information on Function, visit . About Function Health Function Health is a personal health platform that pioneered accessible annual lab testing with over 160 tests at 2,000+ locations nationwide, serving hundreds of thousands of members. The platform tracks all results over time and provides clear clinical explanations alongside actionable insights based on comprehensive medical research. About Ezra Ezra developed FDA-cleared AI technology that makes full body MRI scanning faster and more affordable. The company's technology helps visualize early signs of potential cancer and other health conditions before symptoms appear. SOURCE Function Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED